(Q46611469)

23 December 2017

title

Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis (English)

1 reference

23 December 2017

author name string

Ladabaum U

1

1 reference

23 December 2017

Chey WD

2

1 reference

23 December 2017

Scheiman JM

3

1 reference

23 December 2017

Fendrick AM

4

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

23 December 2017

Alimentary Pharmacology & Therapeutics

published in

1 reference

23 December 2017

volume

16

1 reference

23 December 2017

issue

8

1 reference

23 December 2017

page(s)

1491-1501

1 reference

23 December 2017

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Helicobacter pylori-related disease: guidelines for testing and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Outcomes of initial noninvasive Helicobacter pylori testing in U.S. primary care patients with uninvestigated dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Recent developments in the epidemiology of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Opposing time trends of peptic ulcer and reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Testing for Helicobacter pylori in dyspeptic patients suspected of peptic ulcer disease in primary care: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Omeprazole versus placebo in duodenal ulcer healing. The United States experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Where are We with current therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Treatment of Helicobacter pylori infection: a review of the world literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Prevalence of symptoms of dyspepsia in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Peptic ulcer and Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Helicobacter pylori infection and the risk for duodenal and gastric ulceration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01306.X

10.1046/J.1365-2036.2002.01306.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017